FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease…
Ophthalmology
-
-
Astellas’ Izervay gains conditional approval in Japan for GA treatment
Astellas Pharma has received conditional approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Izervay (avacincaptad pegol…
-
Outlook’s wet AMD candidate hit with second FDA snub in two years
The US Food and Drug Administration (FDA) has rejected Outlook Therapeutics’ bevacizumab for a second time, meaning the company once…
-
Santen and RemeGen sign licence deal for retinal disease injection
Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to…
-
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that…
-
Amphastar and Anji make licence agreement for three new peptides
Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, production, use and commercialisation…
-
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan
Viridian Therapeutics and Kissei Pharmaceutical have signed an exclusive partnership and licence agreement for advancing veligrotug and subcutaneous VRDN-003, potential…
-
Re-Vana Therapeutics and Boehringer Ingelheim collaborate for eye therapies
Re-Vana Therapeutics, a spin-out from Queen’s University, has entered a partnership and licence agreement with Boehringer Ingelheim for the development…
-
Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn
Torrent Pharmaceuticals, headquartered in Gujerat, India, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals…
-
Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency…
